融资余额重回1.9万亿！11家公司融资余额增超10亿！北方稀土、药明康德等备受青睐！

Core Viewpoint - The rapid increase in leveraged funds entering the A-share market since July has led to a significant rise in financing balances, reaching approximately 1.928 trillion yuan by July 24, 2025, indicating strong bullish sentiment among investors [2][4]. Financing Balance Overview - As of July 24, 2025, the financing balance in the A-share market has consistently remained above 1.9 trillion yuan for four consecutive trading days, closely approaching the year's high [2]. - The electronic industry leads in financing balance with approximately 219.1 billion yuan, followed by non-bank financials, computers, power equipment, pharmaceutical biology, machinery, and automotive sectors, all exceeding 100 billion yuan [4][5]. Industry Distribution of Financing Balances - The top industries by financing balance are: - Electronics: 219.1 billion yuan - Non-bank financials: 162.2 billion yuan - Computers: 149.1 billion yuan - Power equipment: 139.8 billion yuan - Pharmaceutical biology: 137.5 billion yuan - Machinery: 101.2 billion yuan - Automotive: 100.6 billion yuan [5][6]. Performance of High Financing Balance Companies - Among the top 30 A-share companies with the highest financing balances, the median increase in stock price since April 7 has been 11.5%, outperforming the Shanghai Composite Index's 7.19% during the same period [7][10]. - Notable companies include Oriental Fortune and China Ping An, both with financing balances exceeding 20 billion yuan, and several others showing significant price increases [7][19]. Resource Stocks and Their Financing Balances - A total of 24 resource stocks have financing balances exceeding 500 million yuan, with 11 of them surpassing 1 billion yuan. North Rare Earth leads with a financing balance of 4.475 billion yuan [12][13]. - The median increase in stock price for resource stocks with financing balances over 500 million yuan since April 7 is 18.55%, significantly higher than the Shanghai Composite Index [12]. Innovative Drug Sector Financing - The innovative drug sector, including CROs, has 34 stocks with financing balances over 500 million yuan, with 11 exceeding 1 billion yuan. WuXi AppTec has the highest financing balance at 3.319 billion yuan [17]. - The median increase in stock price for these innovative drug stocks since April 7 is 15.23%, outperforming the Shanghai Composite Index [17]. Non-Bank Financial Sector Insights - The non-bank financial sector has a total financing balance of approximately 162.2 billion yuan, with 21 stocks having financing balances exceeding 2 billion yuan [19][20]. - The median increase in stock price for these non-bank financial stocks since April 7 is 8.06%, also outperforming the Shanghai Composite Index [19].